To determine whether expression of mesenchymal markers stratifies patient outcome in MM, we analyzed OS using TCGA-SKCM dataset according to ZEB1, CDH2 and CDH1 mRNA levels. The gene discussed is CDH2; the disease is Miyoshi myopathy.